69
Expected LDL-C reduction
at maximum pediatric dose Potential adverse effects
≥50% Myalgias (rare), abdominal pain (rare), accelerated
risk of diabetes type 2 (unknown, reported in adults),
hepatotoxicity (very rare), HMG-CoA antibody
myopathy (very rare) rhabdomyolysis (extremely rare)
30–49%
30–49%
30–49%
≥50%
13–20% Myalgias, muscle weakness, fatigue, diarrhea
(all very rare)
15% Significant drug interactions exist. Contraindicated if
TG are elevated (will raise TG).
Abdominal pain, constipation (rare), pancreatitis
(very rare)
38% (HeFH)
14% (HoFH)
Hypersensitivity (rare), nasopharyngitis (common),
headache, sore throat (common)
34–44% (HeFH)
13% (HoFH)
Nasopharyngitis (common), tonsilitis (common),
headache (common), injection site reaction (common).
Attention and memory problems, syncope were rarely
reported.
48% (HoFH) Fatigue, pyrexia, headache, oropharyngeal pain,
nasopharyngitis, abdominal pain
6–24% GI effects, although these tend to resolve with regular use
6–12% Diarrhea, steatorrhea
Dosing information and contraindications from FDA-approved labeling available at:
http://dailymed.nlm.nih.gov/dailymed/index.cfm
HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial
hypercholesterolemia; IV, intravenous; PO, per os; and SQ, subcutaneous.
